Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | RPTR-168 |
Trade Name | |
Synonyms | RPTR168|RPTR 168 |
Drug Descriptions |
RPTR-168 are autologous T lymphocytes that are targeted against multiple tumor associated antigens (TAAs) and attached to the interleukin IL-12, which bind to tumor cells expressing the TAAs, potentially leading to cytotoxic T-cell mediated killing of these cells and the activation of the anti-tumor immune response (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C179663 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
RPTR-168 | RPTR-168 | 0 | 1 |